Article Text

PDF
Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson’s disease
  1. A H Evans1,2,3,
  2. A D Lawrence4,
  3. A J Lees3
  1. 1
    Department of Neurology, The Royal Melbourne Hospital, Victoria, Australia
  2. 2
    Department of Medicine, University of Melbourne, Australia
  3. 3
    Reta Lila Weston Institute of Neurological Studies and The National Hospital for Neurology and Neurosurgery, London, UK
  4. 4
    Wales Institute of Cognitive Neuroscience, School of Psychology, Cardiff University, Cardiff, UK
  1. Professor A J Lees, Reta Lila Weston Institute of Neurological Studies, Windeyer Building, 46 Cleveland Street, London W1T 4JF, UK; alees{at}ion.ucl.ac.uk

Abstract

Background: Sustained drug therapy in Parkinson’s disease may alter the psychomotor responses to acute challenges with dopaminergic drugs, L-dopa and methylphenidate, and cause cross sensitisation.

Methods: The mood, psychomotor and reward potentiating effects of an acute challenge with L-dopa and methylphenidate on separate occasions were assessed under double blind (medication naïve) conditions after a placebo and then the testing sessions were repeated in the same (medication experienced) patients following a median period of 16.7 months of continuous dopaminergic drug therapy.

Results: In the medication naïve condition, affect was not changed by L-dopa or methylphenidate and only L-dopa improved motor function. In the medication experienced condition, active drugs improved positive affect compared with the medication naïve condition and there was an enhanced effect of L-dopa on motor function. Reward responsivity was enhanced by both L-dopa and methylphenidate in medication naïve and experienced conditions.

Conclusion: Sustained dopaminergic drug therapy augments the motor effects of an acute challenge with L-dopa and induces euphoriant effects to L-dopa and methylphenidate challenges.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

  • Ethics approval: The study was approved by the Joint Ethics Committee of the National Hospital for Neurology and Neurosurgery and Institute of Neurology.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.